Stock Events

Stock Events

Viking Therapeutics 

$34.18
837
-$1.80-5% 16:40 Today

Statistics

Day High
35.79
Day Low
33.96
52W High
43.15
52W Low
22.96
Volume
849,111
Avg. Volume
2,275,593
Mkt Cap
3.99B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.38
-1.03
-0.68
-0.33
Expected EPS
-1.067731
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-359.64MNet Income

Analyst Ratings

94.00Average Price Target
The highest estimate is 114.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VKTX. It's not an investment recommendation.
NVIDIA
195
NVDA
Amazon
152
AMZN
Microsoft
149
MSFT
Palantir Technologies
122
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.73B
Madrigal Pharmaceuticals focuses on the development of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, directly competing with Viking's work on metabolic disorders.
Viking Therapeutics
VKTX
Mkt Cap3.87B
Viking Therapeutics itself, as it's important to consider a company's position and pipeline in comparison to its own progress and future plans.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, positioning it as a competitor in the same therapeutic area as Viking.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.32M
Galmed Pharmaceuticals is developing therapies for liver diseases, including NASH, directly competing with Viking's liver disease focus.
Agios Pharmaceuticals
AGIO
Mkt Cap2B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, overlapping with Viking's interest in metabolic disorders.
Novartis
NVS
Mkt Cap286.78B
Novartis AG has a diverse portfolio that includes treatments for metabolic and liver diseases, making it a competitor in Viking's areas of interest.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad research portfolio that includes metabolic diseases and NASH, positioning it as a competitor to Viking Therapeutics.
AMGEN
AMGN
Mkt Cap224.63B
Amgen focuses on innovative human therapeutics, with a portfolio that includes treatments for cardiovascular and metabolic diseases, competing with Viking's therapeutic areas.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a diverse portfolio in various therapeutic areas, including metabolic diseases, making it a competitor to Viking Therapeutics.

About

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Show more...
CEO
Brian Lian
Employees
65
Country
United States
ISIN
US92686J1060
WKN
000A12GD6

Listings

MI
IT
1VKTX.MI
MU
DE
1VT.MU
XETRA
DE
1VT.XETRA
STU
DE
1VT.STU

0 Comments

Share your thoughts

FAQ

What is Viking Therapeutics stock price today?▼
The current price of VKTX is $34.18 USD — it has decreased by -5% in the past 24 hours. Watch Viking Therapeutics stock price performance more closely on the chart.
What is Viking Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Viking Therapeutics stocks are traded under the ticker VKTX.
Is Viking Therapeutics stock price growing?▼
VKTX stock has risen by +3.37% compared to the previous week, the month change is a -6.4% fall, over the last year Viking Therapeutics has showed a +32.54% increase.
What is Viking Therapeutics market cap?▼
Today Viking Therapeutics has the market capitalization of 3.99B
When is the next Viking Therapeutics earnings date?▼
Viking Therapeutics is going to release the next earnings report on October 28, 2026.
What were Viking Therapeutics earnings last quarter?▼
VKTX earnings for the last quarter are -1.1 USD per share, whereas the estimation was -1.23 USD resulting in a +10.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Viking Therapeutics revenue for the last year?▼
Viking Therapeutics revenue for the last year amounts to 0 USD.
What is Viking Therapeutics net income for the last year?▼
VKTX net income for the last year is -359.64M USD.
How many employees does Viking Therapeutics have?▼
As of August 20, 2026, the company has 65 employees.
In which sector is Viking Therapeutics located?▼
Viking Therapeutics operates in the Health & Wellness sector.
When did Viking Therapeutics complete a stock split?▼
Viking Therapeutics has not had any recent stock splits.
Where is Viking Therapeutics headquartered?▼
Viking Therapeutics is headquartered in SAN DIEGO, United States.